Last updated: February 17, 2026
What is the current market status of drug NDC 00555-0633?
NDC 00555-0633 refers to Camzyos (mavacamten), developed by Bristol-Myers Squibb, approved by the FDA in April 2022. Camzyos is used for treating symptomatic obstructive hypertrophic cardiomyopathy (HOCM). It targets a niche but growing cardiovascular therapy market driven by increased diagnosis of HOCM and unmet needs for symptom management.
What is the size of the current market for Camzyos?
The potential market comprises approximately 30,000 to 50,000 patients in the United States, with a global market expanding proportionally. Market size estimates are based on prevalence data, insurer coverage, and approval status.
Key market drivers include:
-
Prevalence of HOCM: Estimated at 1 in 500 in general population, amounting to roughly 600,000-1,400,000 cases worldwide.
-
Diagnosis rate: Only about 50% are diagnosed early, indicating room for growth.
-
Treatment landscape: Traditionally, surgical myectomy and alcohol septal ablation are standard, but medical therapy options are limited.
-
Regulatory acceptance: Approved in multiple countries, with indications expanding to include broader patient populations.
What are the price projections for Camzyos?
Pricing strategies differ regionally; in the US, the retail list price is approximately $125,000 annually per patient, based on initial estimates when approved (per publicly available data from Bristol-Myers Squibb).
Market penetration assumptions suggest:
- Year 1: 10% of eligible patients, generating approximately $375 million in US sales.
- Year 3: Increasing to 30% penetration, with annual US sales reaching $1.125 billion.
- Global markets: Expansion into Europe, Japan, and emerging markets could add 30-50% to total revenue, with pricing adjusting for local healthcare systems.
Pricing will face pressure from payers and competitors, potentially reducing net prices.
How does Camzyos compare to competing therapies?
Current alternatives primarily involve invasive procedures; no other FDA-approved oral therapies directly target HOCM. Off-label use includes beta-blockers and calcium channel blockers, which have variable efficacy and tolerability.
The absence of direct competition allows premium pricing, but reimbursement challenges could influence actual prices paid.
What are the factors influencing future market access and price?
-
Efficacy and safety profile: Real-world evidence and ongoing trials could impact premiums.
-
Payer coverage: Reimbursement negotiations may lower effective price points.
-
Market penetration: Physician education and access to diagnosis influence uptake.
-
Regulatory expansions: Broader indications could increase patient eligible populations, impacting sales volume and pricing.
What are the long-term outlooks for pricing and market share?
Projections suggest initial high prices, with potential declines as competition or biosimilars enter, or as more cost-effective therapies are developed. A reasonable long-term estimate places the annual market size between $1.5 billion and $2 billion globally within five years, assuming successful commercialization and expanded indications.
Key Takeaways
- Camzyos addresses a niche cardiovascular market with unmet needs.
- US list price: ~$125,000 annually; global pricing varies.
- Market penetration is expected to grow from 10% to 30% within three years.
- Total global sales could reach $1.5-$2 billion annually within five years.
- Pricing will be influenced by payer negotiations, competition, and expanded use.
FAQs
1. What factors could lower Camzyos's price in the future?
Increased competition, biosimilar entry, and payer pressure can reduce effective prices over time.
2. How does the prevalence of HOCM impact market potential?
Higher diagnosed prevalence expands the opportunity, but underdiagnosis limits immediate market size.
3. Are there any regulatory hurdles for expanding Camzyos indications?
Additional trials are required for broader approvals, which can delay market expansion and revenue growth.
4. How significant is international market penetration?
Major European markets and Japan represent key expansion opportunities, potentially adding 30-50% to global sales.
5. What risks could affect sales projections?
Safety concerns, delays in approval for new indications, or payer restrictions can impact market acceptance and revenue.
Sources:
[1] Bristol-Myers Squibb, FDA approval documents for Camzyos, 2022.
[2] IQVIA, Market Access Reports, 2023.
[3] GlobalData, Cardiovascular Market Trends, 2023.
